Advanced Systemic Mastocytosis (AdvSM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : June 12, 2026
- Updated On : September 3, 2026
- Pages : 154
Advanced Systemic Mastocytosis Market Outlook and Forecast
Thelansis’s “Advanced Systemic Mastocytosis (AdvSM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Systemic Mastocytosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Systemic Mastocytosis Overview
Advanced systemic mastocytosis (AdvSM) is a high-risk clonal mast-cell neoplasm characterized most commonly by activating KIT mutations, particularly KIT D816V, leading to accumulation of abnormal mast cells in bone marrow and other organs and causing organ dysfunction, mediator-related symptoms, and substantial morbidity. AdvSM includes aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. Treatment has evolved from conventional cytoreduction and less-selective kinase inhibition toward precision KIT targeting. Avapritinib, a selective KIT inhibitor targeting D816V, has been FDA-approved for adults with AdvSM since 2021 and has produced deep clinical, histologic, biochemical, and molecular responses in many patients. Nevertheless, important unmet needs remain, particularly treatment durability, toxicity management, and control of the associated hematologic neoplasm component in SM-AHN. Next-generation selective KIT inhibition is being pursued, with bezuclastinib undergoing Phase 3 evaluation in AdvSM. Additional research is focused on integrating KIT inhibition with strategies targeting co-occurring myeloid mutations and disease components. For stakeholders, AdvSM represents a mature precision-hematology market in which the next opportunity is moving beyond pathway inhibition alone toward deeper, more durable control across genetically complex disease.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Advanced Systemic Mastocytosis Market Outlook and Forecast
Thelansis’s “Advanced Systemic Mastocytosis (AdvSM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Systemic Mastocytosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Systemic Mastocytosis Overview
Advanced systemic mastocytosis (AdvSM) is a high-risk clonal mast-cell neoplasm characterized most commonly by activating KIT mutations, particularly KIT D816V, leading to accumulation of abnormal mast cells in bone marrow and other organs and causing organ dysfunction, mediator-related symptoms, and substantial morbidity. AdvSM includes aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. Treatment has evolved from conventional cytoreduction and less-selective kinase inhibition toward precision KIT targeting. Avapritinib, a selective KIT inhibitor targeting D816V, has been FDA-approved for adults with AdvSM since 2021 and has produced deep clinical, histologic, biochemical, and molecular responses in many patients. Nevertheless, important unmet needs remain, particularly treatment durability, toxicity management, and control of the associated hematologic neoplasm component in SM-AHN. Next-generation selective KIT inhibition is being pursued, with bezuclastinib undergoing Phase 3 evaluation in AdvSM. Additional research is focused on integrating KIT inhibition with strategies targeting co-occurring myeloid mutations and disease components. For stakeholders, AdvSM represents a mature precision-hematology market in which the next opportunity is moving beyond pathway inhibition alone toward deeper, more durable control across genetically complex disease.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)